Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00565760 · ClinicalTrials.gov registry record · Phase 3
Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain
A Phase 3 study, sponsored by QRxPharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT00565760: Completed Phase 3 study, sponsored by QRxPharma.
NCT00565760 is a Phase 3 study that has completed, run by QRxPharma. The registered enrollment target is 16 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00565760, a Phase 3 study, has completed, sponsored by QRxPharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a Phase 3 double-blind, multiple dose safety extension study of Q8003 administered at daily doses up to 36 mg morphine/24 mg oxycodone (Q8003 36mg/24mg) over a treatment period of up to 4 weeks. Patients with acute moderate to severe pain who have completed participation in one of the designated QRxPharma, Inc. acute pain lead-in studies will be eligible for this trial.
Interventions
- DRUG Placebo
- DRUG Q8003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
What the finished NCT00565760 record still lists
NCT00565760 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00565760 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00565760 about?
NCT00565760 is a clinical study titled "Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain". This is a Phase 3 double-blind, multiple dose safety extension study of Q8003 administered at daily doses up to 36 mg morphine/24 mg oxycodone (Q8003 36mg/24mg) over a treatment period of up to 4 weeks. Patients with acute moderate to severe pain who have completed participation in one of the design...
What is the current status of trial NCT00565760?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2007-11. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00565760?
The interventions under investigation include: Placebo (DRUG), Q8003 (DRUG).
Who is sponsoring clinical trial NCT00565760?
This trial is sponsored by QRxPharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00565760's enrollment target sits among peer trials
16 1974th of 2000 higher than 24 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia